It was evident that patients in the LN active group had higher serum levels of CXCL9 (Figure 4A, 120.37 ± 32.65 pg/mL in LN inactive vs. 145.72 ± 30.68 pg/mL in LN active, p = .003), CXCL10 (Figure 4B, 118.61 ± 30.87 pg/mL in LN inactive vs. 137.04 ± 26.34 pg/mL in LN active, p = .013), and CXCL11 (Figure 4C, 86.59 ± 22.04 pg/mL in LN inactive vs. 107.86 ± 28.57 pg/mL in LN active, p = .004), indicating a correlation between the serum levels of CXCL9, CXCL10, and CXCL11 and the activity level of LN in SLE patients with concurrent LN. This evidence concerns the gene CXCL9 and systemic lupus erythematosus.